Dr. Rugo on the Significance of the MONARCH I Trial for Breast Cancer

Hope S. Rugo, MD
Published: Friday, Jun 02, 2017



Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the significance of the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

According to Rugo, abemaciclib is a different CDK4/6 inhibitor compared to ribociclib (Kisqali) and palbociclib (Ibrance). It appears to have significance as a single agent even for patients who have seen progression after one line of chemotherapy and have received prior taxanes and prior hormone therapy.

There is great excitement to see the results of the combination of abemaciclib with fulvestrant (Faslodex) being investigated in the MONARCH II trial, explains Rugo.
 


Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the significance of the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

According to Rugo, abemaciclib is a different CDK4/6 inhibitor compared to ribociclib (Kisqali) and palbociclib (Ibrance). It appears to have significance as a single agent even for patients who have seen progression after one line of chemotherapy and have received prior taxanes and prior hormone therapy.

There is great excitement to see the results of the combination of abemaciclib with fulvestrant (Faslodex) being investigated in the MONARCH II trial, explains Rugo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x